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Zika virus epidemiology update 
Zika virus epidemiology  
 First isolated from a monkey in Uganda in 1947 
 Before 2007, only sporadic human disease cases 
reported from Africa and southeast Asia 
 In 2007, first outbreak reported on Yap Island, 
Federated States of Micronesia 
 From 2013–2015, >30,000 suspected cases reported 
from French Polynesia and other Pacific islands 
 
 
Hayes et al. Emerg Infect Dis 2009; Duffy et al. N Eng J Med 2009; Cao-Lormeau et al. Emerg Infect Dis 2013. 
Cumulative number of countries reporting mosquito-borne Zika 
virus transmission since 2007, by WHO region (as of Jan 18, 2017) 
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http://www.who.int/emergencies/zika-virus/situation-report/20-january-2017/en/ 
Zika virus in the Americas 
 In May 2015, the first locally acquired cases in the
Americas were reported in Brazil
 As of January 2017, local transmission reported in
50 countries or territories in the Americas
 Only countries without reported local transmission
are Bermuda, Canada, Chile, and Uruguay
www.cdc.gov/zika/geo/active-countries.html 
Locally transmitted Zika virus disease cases reported by 
country/territory in the Americas, 2015–2017 (as of Jan 12, 2017)   
Country (N=50) (N=738,783)* 
Brazil 342,459 (46%) 
Colombia 106,697 (14%) 
Venezuela 61,825 (8%) 
Puerto Rico 37,488 (5%) 
Martinique 36,692 (5%) 
Honduras 32,234 (4%) 
Guadeloupe 31,224 (4%) 
*27% of cases are lab-confirmed 
http://www.paho.org/hq/index.php?option=com_content&view=article&id=12390&Itemid=42090&lang=en 
Suspected and confirmed locally transmitted Zika virus disease 
cases reported in the Americas, 2015–2017 (as of Jan 12, 2017)   
Central America (8%) 
Caribbean (20%) 
South America (70%) 
North America (2%) 
N=738,783 suspected and confirmed cases 
Zika virus in the United States  
 From 2007–2014, 14 Zika virus disease cases identified in 
US travelers 
 With recent outbreaks in the Americas, cases among US 
travelers increased substantially 
 Limited local mosquito-borne transmission identified in 
two states (Florida and Texas) 
 Outbreaks in three US territories (Puerto Rico, US Virgin 
Islands, and American Samoa)  
 
 
Duffy et al. N Eng J Med 2009; Hennessey et al. Am J Trop Med Hyg 2016; Armstrong et al. MMWR 2016; 
Walker et al. MMWR 2016; Likos et al. MMWR 2016; Dirlikov et al. MMWR 2016. 
Laboratory-confirmed Zika virus disease cases reported to ArboNET 
by states or territories — United States, 2015–2017 (as of Jan 25, 2017) 
States  
(N=4,930) 
Territories 
(N=35,784) 
Travel-associated* 4,710 (96%) 140 (<1%) 
Locally acquired 219 (4%) 35,644 (99%) 
Laboratory acquired 1 (<1%) 0 (0%) 
*Includes cases in travelers and their contacts with presumed sexual or in utero transmission,
and one case with unknown route of person-to-person transmission.
www.cdc.gov/zika/geo/united-states.html 
State or territory of residence for reported Zika virus disease 
cases — United States, 2015–2017 (as of Jan 25, 2017)  
www.cdc.gov/zika/geo/united-states.html 
State of residence for reported Zika virus disease cases — 
U.S. states, 2015–2017 (as of Jan 25, 2017)  
State 
Travel associated 
(N=4,711) 
Locally acquired 
(N=219) 
New York 1,001 (21%) 0 (0%) 
Florida 840 (18%) 213 (97%) 
California 411 (9%) 0 (0%) 
Texas 294 (6%) 6 (3%) 
New Jersey 174 (4%) 0 (0%) 
Pennsylvania 171 (4%) 0 (0%) 
Maryland 129 (3%) 0 (0%) 
www.cdc.gov/zika/geo/united-states.html 
Mosquito-borne Zika virus transmission in Florida 
 Beginning in July 2016, sporadic, locally acquired cases identified in 
multiple counties in South Florida 
 Active transmission identified in three small areas of Miami-Dade County 
– Recommendations for pregnant women to avoid travel to those areas 
and pregnant residents to be tested and followed 
– Intensive public health response, including aerial adulticide and 
larvicide applications, helped control the outbreaks  
– No evidence of ongoing, sustained local transmission 
 Likos et al. MMWR 2016; 
http://www.floridahealth.gov/newsroom/2016/10/101116-zika-update.html 
Areas in Miami-Dade County with previous 
active Zika virus transmission  
Mosquito-borne Zika virus transmission in Texas 
 In November 2016, first case of local mosquito-borne Zika virus infection
reported in Brownsville, Texas
 Area borders Mexico with frequent border crossings
 Active Zika virus transmission reported in Mexico near the US-Mexico border
 In December, CDC designated Brownsville a Zika cautionary (yellow) area
– Recommendations for pregnant women to avoid travel to those areas
and pregnant residents to be tested and followed
 As of January 25, six cases of local mosquito-borne transmission reported
from the Brownsville area
www.cdc.gov/zika/intheus/texas-update.html 
Zika cautionary area in Brownsville, Texas 
www.cdc.gov/zika/intheus/texas-update.html 
Numbers of reported Zika virus disease cases — 
U.S. territories, 2015–2017 (as of Jan 25, 2017)  
Territory 
Travel associated 
(N=126) 
Locally acquired 
(N=33,712) 
Puerto Rico 124 (98%) 32,848 (97%) 
US Virgin Islands 2 (2%) 807 (2%) 
American Samoa 0 (0%) 57 (1%) 
http://www.cdc.gov/zika/geo/united-states.html 
Municipality of residence for reported Zika virus disease 
cases — Puerto Rico, 2015–2017 (as of Jan 26, 2017)  
http://www.salud.gov.pr/Estadisticas-Registros-y-Publicaciones/Pages/VigilanciadeZika.aspx 
Age group for reported Zika virus disease cases —  
US states and territories, 2015–2017 (as of Jan 25, 2017)   
0
20
40
60
80
100
<20 20-39 40-59 ≥60 
Pr
op
or
tio
n 
of
 c
as
es
 
Age group (years) 
States (N=4,930)
Territories (N=35,784)
Month of illness onset for Zika virus disease cases —  
US states and territories, 2015–2017 (as of Jan 25, 2017)   
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Month of illness onset 
States (N=4,930)
Territories (N=35,784)
Zika virus transmission and clinical manifestations 
 RNA flavivirus related to dengue, yellow fever,
Japanese encephalitis, and West Nile viruses
 Transmitted to humans primarily by Aedes
(Stegomyia) species mosquitoes
 Typically causes asymptomatic infection or
mild dengue-like illness
 Recent outbreaks identified new modes of
transmission and clinical manifestations
Aedes aegypti 
Aedes albopictus 
Zika virus disease clinical course and outcomes 
 Most infections asymptomatic
 Clinical illness usually mild
 Characterized by fever, rash, arthralgia, or conjunctivitis
 Symptoms last several days to a week
 Severe disease requiring hospitalization uncommon
 Fatalities rare
Duffy et al. N Engl J Med 2009; Walker et al. MMWR 2016; Armstrong et al. MMWR 2016; Dirlikov et al. MMWR 2016. 
Clinical manifestations newly identified in 2015‒2016 
 Fetal loss
 Microcephaly and other congenital anomalies
 Guillain-Barré syndrome and other neurologic syndromes
 Thrombocytopenia
Meaney-Delman et al. MMWR 2016; Cauchemez et al. Lancet 2016; Rasmussen et al. N Eng J Med 2016; 
Moore et al. JAMA Pediatr 2016; de Araujo et al. Lancet Infect Dis 2016; Cao-Lormeau et al. Lancet 2016; 
Sharp et al. Clin Infect Dis 2016.  
Non mosquito-borne modes of transmission  
 Documented 
–
–
–
–
–
–
–
–
Intrauterine resulting in congenital infection 
Intrapartum from viremic mother to newborn 
Sexual 
Laboratory exposure 
Blood transfusion 
 Possible 
Organ or tissue transplantation  
Breast milk 
Other body fluids 
 
 
Risk of adverse outcomes of pregnancy 
 Incidence and clinical spectrum of congenital Zika virus 
infection unknown 
 Risk of fetal loss and congenital anomalies appear to be 
greater with infections early in pregnancy 
 Estimated 1‒13% risk of congenital microcephaly following 
Zika virus infection during the first trimester of pregnancy 
 
Johansson et al. N Engl J Med 2016; Cauchemez et al. Lancet 2016; Rasmussen et al. N Eng J Med 2016; 
Moore et al. JAMA Pediatr 2016.   
 
 
 
Microcephaly or other CNS malformations possibly associated 
with Zika virus infection reported to WHO (as of Jan 20, 2017)*   
Country/territory (N=29) (N=2,635) 
Brazil 2,366 (90%) 
Colombia 78 (3%) 
United States 41 (2%) 
Dominican Republic 22 (1%) 
Martinique 18 (1%) 
French Guiana 16 (1%) 
Guatemala 15 (1%) 
22 other countries/territories 79 (3%) 
*Includes cases acquired in other countries 
http://www.who.int/emergencies/zika-virus/situation-report/20-january-2017/en/ 
Clinical findings in infants with congenital Zika virus infection 
Brain anomalies  
 Subcortical calcifications 
 Ventriculomegaly 
 Abnormal gyral patterns 
 Corpus callosum agenesis 
 Cerebellar hypoplasia 
Ocular anomalies 
 Microphthalmia 
 Cataracts 
 Chorioretinal atrophy 
 Optic nerve hypoplasia 
 
Moore et al. N Engl J Med 2016. 
Neurologic sequelae 
 Hypertonia/hypotonia 
 Irritability 
 Tremors 
 Swallowing dysfunction 
 Hearing loss 
 Visual impairment 
Congenital contractures 
 Clubfoot 
 Arthrogryposis 
Zika virus perinatal transmission  
 Two case reports from French Polynesia  
 Both women developed mild rash illness within 3 days of delivery 
 One infant developed a transient rash and mild thrombocytopenia 
at 3 days of life 
 Second infant remained asymptomatic 
 Both mothers and infants had Zika virus RNA in serum 
 Newborns had otherwise unremarkable clinical course 
Besnard et al. Euro Surveill 2014. 
Zika virus sexual transmission  
 Identified in sexual partners with discordant travel history 
 First report in 2011 in returning traveler from Senegal 
 In 2016, sexually transmitted cases reported from 12 
countries, including 38 cases in the United States 
 Most reported cases result from men with symptomatic 
illness transmitting to their female or male partner 
– One report of transmission from a woman to a man 
– Two reports of transmission from asymptomatic men 
 Foy et al. Emerg Infect Dis 2011; Hills et al. MMWR 2016; Russell et al. Clin Infect Dis 2016; 
Davidson et al. MMWR 2016; Brooks et al. MMWR 2016; Freor et al. Euro Surveill 2016. 
Zika virus in semen and vaginal fluid 
 Zika viral RNA detected in semen up to 6 months after illness 
onset and in vaginal fluid up to 2 weeks after illness onset 
 Zika virus cultured from semen up to 70 days after illness onset 
 Sexual transmission reported up to 40 days after illness onset 
in the transmitting partner 
 Data from case reports and may not reflect true incidence or 
risk of transmission 
Barzon et al. Euro Surveill 2016; D’Ortenzio et al. N Eng J Med 2016; Arsuaga et al. Lancet Infect Dis 2016; Freor et al. Euro 
Surveill 2016; Prisant et al. Lancet Infect Dis 2016; Nicastri et al. Emerg Infect Dis 2016; Dudley et al. Nature Comm 2016. 
Impact of Zika virus sexual transmission 
 Incidence, duration, and risk factors for sexual transmission unknown 
 One modeling study from Brazil suggested the apparent increased 
incidence of disease in women is due to sexual transmission 
 Another model determined that sexual transmission is not a 
significant factor in driving an outbreak 
 Two prospective cohort studies in United States ongoing to evaluate 
frequency and duration of Zika virus RNA and live virus in semen 
Coehlo et al. bioRxiv 2016; Yakob et al. Lancet Infect Dis 2016. 
Transfusion-transmitted Zika virus infections 
 Zika virus RNA identified in 42 (3%) of 1,505 blood donors in French 
Polynesia in 2013–2014; none of the products were transfused 
 In 2016, at least 3 cases of transfusion transmitted Zika virus 
infections have been reported from Brazil 
 In February 2016, FDA issued recommendations to reduce the risk 
of transfusion-transmitted Zika virus in the United States 
 From April–December, 2016, routine screening identified Zika virus 
RNA in 360 (0.6%) of 54,588 blood donations in Puerto Rico 
 In August 2016, FDA recommended routine Zika virus screening of 
all blood donations in the United States 
Musso et al. Euro Surveill 2014; Lanteri et al. Transfusion 2016; Motta et al. N Engl J Med 2016; Kuehnert et al. MMWR 2016. 
Zika virus laboratory transmission 
 From 1964‒1980, there were 4–6 reports of probable 
Zika virus infections due to laboratory exposure 
 In 2016, one report of confirmed Zika virus infection 
following a needle stick injury in US researcher 
– Mild symptomatic illness without complications 
Simpson et al. Trans Roy Soc Trop Med Hyg 1964; Filipe et al. Archiv fur gesante virusforschung 1973; 
ACAV et al. Am J Trop Med Hyg 1980 
Zika virus in breast milk 
 Zika virus transmission through breast milk has not been documented 
 Zika virus RNA detected in breast milk collected several days after onset 
of illness in two women with perinatal transmission in French Polynesia 
– Viral culture negative on breast milk 
 Zika virus RT-PCR and culture positive on breast milk collected 4 days 
after onset of illness in a woman in New Caledonia 
– Infant asymptomatic and no laboratory evidence of infection  
 Benefits of breastfeeding outweigh theoretical risk of transmission 
 
Besnard et al. Euro Surveill 2014; Colt et al. Bull WHO 2016 
Zika virus transmission from other body fluids 
 Zika virus RNA has been detected in saliva and tears 
 One case of possible person-to-person transmission reported from Utah 
 Index patient developed fatal septic shock and had a level of viremia 
approximately 100,000 times higher than average  
 Zika virus infection diagnosed in a family member who had close contact 
(i.e., kissing and touching) with the index case in days prior to death 
 No specific source or mode of transmission was identified 
 No additional infections identified in 18 other family members or 
healthcare workers who cared for the patient  
Brent et al. MMWR 2016 
Guillain-Barré syndrome following Zika virus infection 
 First described in French Polynesia during 2013‒2014 outbreak
 Additional 19 countries have now reported at least one Guillain-Barré
syndrome case with laboratory evidence of Zika virus infection
 13 GBS cases reported from US states and 50 from Puerto Rico
 Estimated 1.6 cases of Guillain-Barré syndrome per 10,000 Zika virus
infections (95% CI 1.1–2.6 per 10,000)
 Outcomes and increased risk in older adults appear similar to
Guillain-Barré syndrome due to other causes
Oeh ler et al. Euro Surveill 2014; Dirlikov. Emerg Infect Dis 2016; Dirlikov. MMWR 2016 
http://www.who.int/emergencies/zika-virus/situation-report/8-december-2016/en/ 
www.cdc.gov/zika/geo/united-states.html  
Neurologic disease with non-congenital Zika virus infections 
 Rare reports of encephalopathy, meningoencephalitis, 
myelitis, and uveitis 
 Reports of peripheral paresthesias, with or without 
Guillain-Barré syndrome  
 
 
 
Roze et al. Eurosurv 2016; Carteaux et al. N Eng J Med 2016; Mecharles et al. Lancet 2016; 
Fortado et al. N Eng J Med 2016  
 
 
Risk of thrombocytopenia and hemorrhage 
 Estimated 1% of symptomatic Zika virus disease cases may 
have thrombocytopenia (platelet count <100,000) 
 Rare reports of severe thrombocytopenia with hemorrhage or 
septic shock, including at least two fatal cases 
Sharp et al. Clin Infect Dis 2016; Dirlikov et al. MMWR 2016; Brent et al. MMWR 2016. 
 
 
 
Zika virus treatment and prevention  
 Reduce mosquito exposure through vector control and personal 
protective measures (e.g., insect repellent and air conditioning) 
 Pregnant women should not travel to areas with local  transmission 
and take steps to protect against possible sexual transmission  
 No vaccine or medication to prevent or treat infection or disease 
–
–
–
 
Numerous candidate vaccines being evaluated 
Coordinated US government effort to facilitate development 
Targeted use will depend on ongoing incidence of disease and 
complications, and vaccine characteristics (e.g., safety, efficacy, 
and duration of protection) 
 
 
For more information, contact CDC 
1-800-CDC-INFO (232-4636) 
TTY:  1-888-232-6348    www.cdc.gov 
 
 
The findings and conclusions in this report are those of the authors and do not necessarily represent the 
official position of the Centers for Disease Control and Prevention. 
